

PVE

FORM PTO-1449 TO BE FILED WITH INFORMATION DISCLOSURE STATEMENT

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No. 1259-064 Serial No. 09/035,708

INFORMATION
DISCLOSURE STATEMENT
BY APPLICANTS

Zemlan et al.

Applicant


March 5, 1998

Filing Date

1643

Group Art Unit

J. Hayes
Examiner's name



U.S. PATENT DOCUMENTS

Examiner's Initial	Document Number	Date	Name	Class/Sub-class
	None			

FOREIGN PATENT DOCUMENTS

Examiner's Initial	Document Number	Date	Country/Name	Translation? yes/no
<u>PCH</u>	WO 93/03369	02/93	<u>PCT</u> <u>WO</u>	N/A
<u>J</u>	WO 93/08302	04/93	<u>PCT</u> <u>WO</u>	N/A
<u>J</u>	WO 93/11231	06/93	<u>PCT</u> <u>WO</u>	N/A
<u>J</u>	WO 94/13795	06/94	<u>PCT</u> <u>WO</u>	N/A
<u>J</u>	WO 95/17429	06/95	<u>PCT</u> <u>WO</u>	N/A
<u>J</u>	WO 96/04309	02/96	<u>PCT</u> <u>WO</u>	N/A

P. Hayes 1/18/00

OTHER DOCUMENTS

not a
reference
itself

~~International Search Report for International Application No. PCT/US99/04955, mailed June 11, 1999.~~

FILE



**FORM PTO-1449 TO BE FILED WITH
INFORMATION DISCLOSURE STATEMENT**

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No. 1259-064 Serial No. 09/035,708

INFORMATION
DISCLOSURE STATEMENT
BY APPLICANTS

Zemlan et al.

Applicant

March 5, 1998

Filing Date

1643 1644

Group Art Unit

1 pages

Examiner's name

U.S. PATENT DOCUMENTS

Examiner's Initial	Document Number	Date	Name	Class/Sub-class
	5,601,985	02/97	Trojanowski et al.	435/7.1
	5,492,812	02/96	Vooheis	435/7.1
<i>no</i>	5,486,460	01/96	Townsend	435/40.51
<i>copies</i>	5,262,332	11/93	Selkoe	436/518
	5,234,814	08/93	Card et al.	435/7.21
	5,200,324	04/06/93	Navaratnam et al.	435/20
	5,190,629	03/93	Sugihara et al.	204/182.8

FOREIGN PATENT DOCUMENTS

Examiner's Initial	Document Number	Date	Country/Name	Translation? yes/no
	PCT/AU92/00610	11/91	AU	YES
<i>no</i>	PCT/BE91/00083	11/90	BE	NO
	PCT/EP92/02392	10/91	EP	YES
<i>copies</i>	PCT/EP95/03032	07/94	EP	YES
	PCT/GB91/00545	04/90	GB	YES
<i>provided</i>	PCT/US92/06700	08/91	US	YES
	PCT/US92/08470	10/92	US	YES
	PCT/US93/09310	10/92	US	YES
	PCT/US94/08903	08/94	US	YES

<i>no copies</i>	PCT/US94/13841	11/94	US	YES
	PCT/US95/09445	07/95	US	YES
	91120974.0	12/91	EP	YES
	93105149.4	03/93	EP	YES

OTHER DOCUMENTS

1. Roush, Science, 277 (July 1997) 31-32.
2. Roush, Science, 267 (Feb. 1995) 793-794.
3. Faulkner, Lab Report, 18(7/8) July/August 53-59.

no copies

Examiner <i>P. Vayer</i>	Date Considered <i>1/18/00</i>
--------------------------	--------------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

The identification of any document herein is not intended to be, and should not be understood as being, an admission that each such document, in fact, constitutes "prior art" within the meaning of applicable law since, for example, a given document may have a later effective date than at first seems apparent or the document may have an effective date which can be antedated. The "prior art" status of any document is a matter to be resolved during prosecution.



**FORM PTO-1449 TO BE FILED WITH
INFORMATION DISCLOSURE STATEMENT**

U.S. Department of Commerce Atty. Docket No. 1259-064 Serial No. 09/035,708
Patent and Trademark Office

INFORMATION Zemlan et al.
DISCLOSURE STATEMENT Applicant
BY APPLICANTS March 5, 1998 1643 1644
Filing Date Group Art Unit
 PCN
Examiner's name

U.S. PATENT DOCUMENTS

Examiner's Initial	Document Number	Date	Name	Class/Sub-class
<u>no copy</u>	<u>5,733,734</u>	<u>03/31/98</u>	<u>Trojanowski et al.</u>	<u>435/7.1</u>

FOREIGN PATENT DOCUMENTS

Examiner's Initial	Document Number	Date	Country/Name	Translation? yes/no
	NONE			

OTHER DOCUMENTS

no
copies
provided

1. Rosengren et al., Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF, *J. of Neurochemistry* 67(5):2013-2018 (1996).
2. Adams et al., Diffuse Axonal Injury in Head Injury: Definition, Diagnosis and Grading, *Histopathology* 15:49-59 (1989).
3. Gotow and J. Tanaka, Phosphorylation of Neurofilament H. Subunit as Related to Arrangement of Neurofilaments, *J. Neuroscience Res.*, 37:691-713 (1994).

4. Binder et al., The Distribution of Tau in the Mammalian Central Nervous System, *J. Cell Biology*, 101:1371-1378 (1985).
5. Greenberg et al., Hydrofluoric Acid-treated τ _{PHF} Proteins Display the Same Biochemical Properties as Normal τ , *J. of Biochemical Chem.*, 267(1):564-569 (1992).
6. Kosik and E. Finch, MAP2 and Tau Segregate into Dendritic and Axonal Domains After the Elaboration of Morphologically Distinct Neurites: An Immunocytochemical Study of Cultured Rat Cerebrum, *J. Neuroscience*, 7(10):3142-3153 (1987).
7. Kosik et al., Developmentally Regulated Expression of Specific Tau Sequences, *Neuron* 2:1389-1397 (1989).
8. Litman et al., Subcellular Localization of Tau mRNA in Differentiating Neuronal Cell Culture: Implications for Neuronal Polarity, *Neuron* 10:627-638 (1993).
9. Wolozin et al., A Neuronal Antigen in the Brains of Alzheimer Patients, *Science*, 232:648-650.
10. Caputo et al., Immunological Characterization of the Region of Tau Protein That is Bound to Alzheimer Paired Helical Filaments, *Neurobiology of Aging*, 13:267-274 (1992).
11. Endoh et al., Lack of Carboxyl Terminal Sequence of Tau in Ghost Tangles of Alzheimer's Disease, *Brain Res.*, 601:164-170 (1993).
12. Carmel et al., The Structural Basis of Monoclonal Antibody Alz50's Selectivity for Alzheimer's Disease Pathology, *J. Biological Chem.*, 271(51):32789-32795 (1996).
13. Otvos et al., Monoclonal Antibody PHF-1 Recognizes Tau Protein Phosphorylated at Serine Residues 396 and 404, *J. of Neuroscience Res.*, 39:669-673 (1994).
14. Zemlan and G. Dean, Monoclonal Antibody PHF-9 Recognizes Phosphorylated Serine 404 of Tau Protein and Labels Paired Helical Filaments, *J. Neuroscience Res.*, 46:90-97.
15. Lee and S. Rook, Expression of Tau Protein in Non-neuronal Cells: Microbulule Binding and Stabilization, *J. of Cell Sci.*, 102:227-237(1992).
16. Anderton et al., Monoclonal Antibodies Show That Neurofibrillary Tangles and Neurofilaments Share Antigenic Determinants, *Nature* 298:84-86 (1982).

no
copies



- no copies
17. Goedert et al., Multiple Isoforms of Human Microtubule-Associated Protein Tau: Sequences and Localization in Neurofibrillary Tangles of Alzheimer's Disease, *Neuron*, 3:519-526 (1989).
 18. Arai et al., Cerebrospinal Fluid Tau Levels in Neurodegenerative Diseases with Distinct Tau-Related Pathology, *Biochem. and Biophysical Res. Comm.*, 236:262-264 (1997).
 19. Mori et al., Tau in Cerebrospinal Fluids: Establishment of the Sandwich ELISA with Antibody Specific to the Repeat Sequence in Tau, *Neurosci. Letters*, 186:181-183 (1995).
 20. Johnson et al., The τ Protein in Human Cerebrospinal Fluid in Alzheimer's Disease Consists of Proteolytically Derived Fragments, *J. NeuroChemistry*, 68(1):430-433 (1997).
 21. Munroe et al., Tau Protein in Cerebrospinal Fluid as an Aid in Diagnosis of Alzheimer's Disease, *Annals of Clinical and Lab. Sci.*, 25(3):207-217.
 22. Vigo-Pelfrey et al., Elevation of Microtubule-associated Protein Tau in the Cerebrospinal Fluid of Patients With Alzheimer's Disease, *Neurology*, 45:788-793 (1995).
 23. Lycke et al., Neurofilament Protein in Cerebrospinal Fluid: A Potential Marker of Activity in Multiple Sclerosis, *Short Report* (1997).
 24. Tullberg et al., CSF Neurofilament and Glial Fibrillary Acidic Protein in Normal Pressure Hydrocephalus, *Neurology*, 50:1122-1127.
 25. Greenberg et al., Hydrofluoric Acid-treated τ PHF Proteins Display the Same Biochemical Properties as Normal τ^* , *J. Biological Chem.*, 267(1):564-569.

Examiner <u>P. I. Lauer</u>	Date Considered <u>1/18/00</u>
-----------------------------	--------------------------------

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

The identification of any document herein is not intended to be, and should not be understood as being, an admission that each such document, in fact, constitutes "prior art" within the meaning of applicable law since, for example, a given document may have a later effective date than at first seems apparent or the document may have an effective date which can be antedated. The "prior art" status of any document is a matter to be resolved during prosecution.

